RT Journal Article
SR Electronic
T1 Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.21249432
DO 10.1101/2021.01.08.21249432
A1 Chen, Siyu
A1 Flegg, Jennifer A
A1 White, Lisa J
A1 Aguas, Ricardo
YR 2021
UL http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249432.abstract
AB Accurate knowledge of levels of prior population exposure will inform preparedness plans for subsequent SARS-CoV-2 epidemic waves and vaccination strategies. Serological studies can be used to estimate levels of past exposure and thus position populations in their epidemic timeline. To circumvent biases introduced by decaying antibody titers over time, population exposure estimation methods should account for seroreversion. Here, we present a new method that combines multiple datasets (serology, mortality, and virus positivity ratios) to estimate seroreversion time and infection fatality ratios and simultaneously infer population exposure levels. The results indicate that the average time to seroreversion is five months, meaning that true exposure may be more than double the current seroprevalence levels reported for several regions of England.Summary SARS-CoV-2 exposure in England could be double the reported seroprevalence, with implications for the impact of vaccines/other interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJF acknowledges receives funding from the Australian Research Council (DP200100747). LJW is funded by the Li Ka Shing Foundation, and the University of Oxford's COVID-19 Research Response Fund (BRD00230). RA is funded by the Bill and Melinda Gates Foundation (OPP1193472).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, code, and materials used in the analyses can be accessed at:https://github.com/SiyuChenOxf/COVID19SeroModel/tree/master